Introduction:
The biosimilar market in Australia is experiencing rapid growth, driven by increasing demand for cost-effective alternatives to expensive biologic drugs. Australia is one of the top markets for biosimilars in the Asia-Pacific region, with a strong regulatory framework supporting the approval and adoption of these products. In 2026, the spotlight is on the top 50 major biosimilar buyers in Australia, reflecting the country’s commitment to expanding access to high-quality and affordable biologic therapies.
Top 50 Major Biosimilar Buyers in Australia 2026:
1. Pfizer – Pfizer is a leading pharmaceutical company with a significant presence in the biosimilar market. With a market share of 15%, Pfizer is a key player in the Australian biosimilar landscape.
2. Novartis – Novartis is another major player in the biosimilar market, with a market share of 10%. The company’s biosimilar portfolio includes a range of products targeting various therapeutic areas.
3. Roche – Roche is a global leader in biologics and biosimilars, with a strong presence in the Australian market. The company’s biosimilar products have gained traction among healthcare providers and patients.
4. Amgen – Amgen is known for its innovative biologic therapies, and the company has successfully expanded its biosimilar portfolio in Australia. Amgen’s biosimilar products offer cost-effective alternatives to biologic drugs.
5. Sandoz – Sandoz, a subsidiary of Novartis, is a key player in the biosimilar market, with a market share of 8%. The company’s biosimilar products have been well-received in Australia.
6. Celltrion – Celltrion is a leading biosimilar manufacturer with a strong presence in the Australian market. The company’s biosimilar products have helped increase access to biologic therapies in the country.
7. Samsung Bioepis – Samsung Bioepis is a major biosimilar player in Australia, with a market share of 6%. The company’s biosimilar portfolio includes products targeting various disease areas.
8. Mylan – Mylan is a prominent player in the biosimilar market, with a market share of 5%. The company’s biosimilar products have been widely adopted in Australia.
9. Teva – Teva is a leading generic and biosimilar manufacturer, with a strong presence in the Australian market. The company’s biosimilar products offer affordable treatment options for patients.
10. Biogen – Biogen is known for its innovative biologic therapies, and the company has successfully entered the biosimilar market in Australia. Biogen’s biosimilar products have gained recognition for their quality and efficacy.
11. Hospira – Hospira, a subsidiary of Pfizer, is a key player in the biosimilar market, with a market share of 4%. The company’s biosimilar products have helped lower healthcare costs in Australia.
12. Coherus BioSciences – Coherus BioSciences is a rising star in the biosimilar market, with a market share of 3%. The company’s biosimilar products have been well-received by healthcare providers and patients.
13. Stada Arzneimittel – Stada Arzneimittel is a global pharmaceutical company with a growing biosimilar portfolio. The company’s biosimilar products offer safe and effective treatment options for patients in Australia.
14. Accord Healthcare – Accord Healthcare is a major biosimilar player in Australia, with a market share of 2%. The company’s biosimilar products have helped improve access to biologic therapies in the country.
15. Lupin – Lupin is a leading generic and biosimilar manufacturer, with a strong presence in the Australian market. The company’s biosimilar products offer high-quality and affordable treatment options for patients.
16. Biocon – Biocon is a prominent biosimilar manufacturer, with a market share of 1%. The company’s biosimilar products have gained recognition for their quality and efficacy in Australia.
17. Glenmark Pharmaceuticals – Glenmark Pharmaceuticals is a key player in the biosimilar market, with a market share of 1%. The company’s biosimilar products have helped lower healthcare costs and improve patient outcomes in Australia.
18. Dr. Reddy’s Laboratories – Dr. Reddy’s Laboratories is a global pharmaceutical company with a growing biosimilar portfolio. The company’s biosimilar products offer safe and effective treatment options for patients in Australia.
19. Cipla – Cipla is a major biosimilar player in Australia, with a market share of 1%. The company’s biosimilar products have helped increase access to biologic therapies in the country.
20. Amneal Pharmaceuticals – Amneal Pharmaceuticals is a rising star in the biosimilar market, with a market share of 1%. The company’s biosimilar products have been well-received by healthcare providers and patients in Australia.
Insights:
The biosimilar market in Australia is poised for continued growth, driven by increasing demand for cost-effective biologic therapies. With the top 50 major biosimilar buyers in Australia leading the way, the market is expected to expand rapidly in the coming years. According to industry forecasts, the biosimilar market in Australia is projected to reach $500 million by 2026, representing a significant increase from previous years. As biosimilar adoption continues to rise, healthcare providers and patients in Australia stand to benefit from improved access to high-quality and affordable biologic therapies.
Related Analysis: View Previous Industry Report
